LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC-Reference-Cited by-同舟云学术

LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC

Published:2023-04 Issue:4 Volume:4 Page:100490
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Alexander Marliese^ORCID,Wei Joe,Parakh Sagun,John Thomas,Kao Steven,Nagrial Adnan,Bowyer Samantha,Warburton Lydia,Moore Melissa,Hughes Brett G.M.,Clay Timothy D.,Pavlakis Nick,Solomon Benjamin J.,Itchins Malinda

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference43 articles.

1. Lung cancer in Australia;John;J Thorac Oncol,2020

2. EML4-ALK variants: biological and molecular properties, and the implications for patients;Sabir;Cancers (Basel),2017

3. Catalog of 5' fusion partners in ALK-positive NSCLC circa 2020;Ou;JTO Clin Res Rep,2020

4. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

5. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study;Mok;Ann Oncol,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real world study of safety and efficacy of lorlatinib as second line and beyond in ALK-rearranged advanced non-small cell lung cancer patients in India – a multicentre chart review study (ROSELAND);ecancermedicalscience;2024-02-13

2. Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions;Biomedicines;2024-01-27

3. From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC);Diagnostics;2023-12-25

4. Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma—RIOMeso;Journal of Thoracic Oncology;2023-11